The president wants a the most-favored-nation pricing model. But the U.S. drug industry is offering a host of reasons why ...

(Reuters) -Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Trump administration officials are expected to release more details on their plan to lower prescription drug prices in the ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Wall Street investors closely monitoring trade discussions between the US and China drove stocks higher as Commerce Secretary ...

Wall Street investors closely monitoring trade discussions between the US and China drove stocks higher as Commerce Secretary ...

While pharmaceutical executives raise valid concerns about the lack of detailed implementation plans for the “Most Favored ...

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and ...

Republican presidential candidate Donald Trump has proposed a “Most Favored Nation” pricing plan to lower the cost of ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...